{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:48:46Z","timestamp":1780051726978,"version":"3.53.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Progetto di Ricerca di Ateneo 2014","award":["PDA141311"],"award-info":[{"award-number":["PDA141311"]}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG18855"],"award-info":[{"award-number":["IG18855"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Marie Sk\u0142odowska-Curie Individual Fellowship","award":["798105"],"award-info":[{"award-number":["798105"]}]},{"name":"FINDER"},{"DOI":"10.13039\/501100010607","name":"University of Perugia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.antiviral.2019.03.003","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T17:16:14Z","timestamp":1552670174000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA-PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3227-1537","authenticated-orcid":false,"given":"Giulio","family":"Nannetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-8045","authenticated-orcid":false,"given":"Beatrice","family":"Mercorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bertagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Desantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Pal\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Tabarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Loregian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.03.003_bib1","doi-asserted-by":"crossref","first-page":"8414","DOI":"10.1074\/jbc.M110.205534","article-title":"Disruption of the viral polymerase complex assembly as a novel approach to attenuate influenza A virus","volume":"286","author":"M\u00e4nz","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.03.003_bib2","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib3","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.03.003_bib4","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1038\/ncomms5794","article-title":"Generation and characterization of influenza A viruses with altered polymerase fidelity","volume":"5","author":"Cheung","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2019.03.003_bib5","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.003_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ejmech.2018.08.032","article-title":"Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction","volume":"157","author":"D'Agostino","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.003_bib7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1254\/jphs.14156SC","article-title":"Characterization of susceptibility variants of influenza virus grown in the presence of T-705","volume":"126","author":"Daikoku","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.antiviral.2019.03.003_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejmech.2017.06.015","article-title":"Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity","volume":"138","author":"Desantis","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.003_bib9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejmech.2018.07.009","article-title":"Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity","volume":"156","author":"Desantis","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.003_bib10","article-title":"Adamantane-resistant influenza A viruses in the world (1902\u20132013): frequency and distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.003_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4149\/av_2013_02_113","article-title":"The RNA polymerase of influenza a virus: mechanisms of viral transcription and replication","volume":"57","author":"Fodor","year":"2013","journal-title":"Acta Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbagen.2011.11.003","article-title":"Structure-based discovery of anti-influenza virus A compounds among medicines","volume":"1820","author":"Fukuoka","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.antiviral.2019.03.003_bib13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.03.003_bib14","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza a (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.03.003_bib15","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1128\/JVI.00724-07","article-title":"Peptide-mediated interference with influenza A virus polymerase","volume":"81","author":"Ghanem","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib16","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.03.003_bib17","doi-asserted-by":"crossref","first-page":"e01217","DOI":"10.1128\/JVI.01217-18","article-title":"Determining the mutation bias of favipiravir in influenza virus using next-generation sequencing","volume":"93","author":"Goldhill","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib18","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1093\/nar\/24.22.4456","article-title":"Identification of two separate domains in the influenza virus PB1 protein involved in the interaction with the PB2 and PA subunits: a model for the viral RNA polymerase structure","volume":"24","author":"Gonz\u00e1lez","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.03.003_bib19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","article-title":"Influenza virus neuraminidase inhibitors","volume":"355","author":"Gubareva","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2019.03.003_bib20","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/j.1460-2075.1985.tb04038.x","article-title":"The molecular basis of the specific anti-influenza action of amantadine","volume":"4","author":"Hay","year":"1985","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2019.03.003_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.003_bib22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nature07120","article-title":"Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus","volume":"454","author":"He","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.03.003_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2017.07.016","article-title":"Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses","volume":"145","author":"Hu","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.003_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S105473","article-title":"Drug resistance in influenza A virus: the epidemiology and management","volume":"10","author":"Hussain","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.antiviral.2019.03.003_bib25","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1016\/j.bmcl.2013.08.048","article-title":"Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza A virus","volume":"23","author":"Kessler","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2019.03.003_bib26","doi-asserted-by":"crossref","first-page":"S371","DOI":"10.1093\/ofid\/ofx163.910","article-title":"Synergistic antiviral activity of S-033188\/S-033447, a novel inhibitor of influenza virus cap-dependent endonuclease, in combination with neuraminidase inhibitors in vitro","volume":"4","author":"Kitano","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.003_bib27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.antiviral.2019.03.003_bib28","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1473-3099(16)00153-5","article-title":"Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997-2015: a systematic review of individual case data","volume":"16","author":"Lai","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.003_bib29","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1021\/jm500300r","article-title":"Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds","volume":"57","author":"Lepri","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.003_bib30","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.3390\/v7092850","article-title":"Clinical implications of antiviral resistance in influenza","volume":"7","author":"Li","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.03.003_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.chembiol.2005.12.002","article-title":"Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase","volume":"13","author":"Loregian","year":"2006","journal-title":"Chem. Biol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib32","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/jcp.20356","article-title":"Disruption of protein-protein interactions: towards new targets for chemotherapy","volume":"204","author":"Loregian","year":"2005","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/rmv.356","article-title":"Protein-protein interactions as targets for antiviral chemotherapy","volume":"12","author":"Loregian","year":"2002","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib34","doi-asserted-by":"crossref","first-page":"8336","DOI":"10.1128\/JVI.77.15.8336-8344.2003","article-title":"Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit","volume":"77","author":"Loregian","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1128\/JVI.78.1.158-167.2004","article-title":"Residues of human cytomegalovirus DNA polymerase catalytic subunit UL54 that are necessary and sufficient for interaction with the accessory protein UL44","volume":"78","author":"Loregian","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib36","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s00018-014-1615-2","article-title":"Antiviral strategies against influenza virus: towards new therapeutic approaches","volume":"71","author":"Loregian","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.antiviral.2019.03.003_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2016.07.019","article-title":"Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance","volume":"133","author":"Ma","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.003_bib38","doi-asserted-by":"crossref","first-page":"10118","DOI":"10.1021\/jm401560v","article-title":"Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly","volume":"56","author":"Massari","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.003_bib39","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1021\/acs.jmedchem.5b00012","article-title":"A broad anti-influenza hybrid small molecule that potently disrupts the interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) subunits","volume":"58","author":"Massari","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.003_bib40","doi-asserted-by":"crossref","first-page":"7699","DOI":"10.1021\/acs.jmedchem.5b01474","article-title":"Polymerase acidic protein\u2013basic protein 1 (PA\u2013PB1) protein\u2013protein interaction as a target for next-generation anti-influenza therapeutics","volume":"59","author":"Massari","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.003_bib41","doi-asserted-by":"crossref","first-page":"7944","DOI":"10.1039\/C7OB02085F","article-title":"Efficient and regioselective one-step synthesis of 7-aryl-5-methyl- and 5-aryl-7-methyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivatives","volume":"15","author":"Massari","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.antiviral.2019.03.003_bib42","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dks150","article-title":"In vitro passaging of a pandemic H1N1\/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir","volume":"67","author":"McKimm-Breschkin","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2019.03.003_bib43","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1128\/JVI.76.11.5380-5386.2002","article-title":"In vitro selection and characterization of influenza A (A\/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675","volume":"76","author":"Molla","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib44","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1056\/NEJMp0900648","article-title":"Global transmission of oseltamivir-resistant influenza","volume":"360","author":"Moscona","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.03.003_bib45","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1099\/vir.0.80518-0","article-title":"Increased amounts of the influenza virus nucleoprotein do not promote higher levels of viral genome replication","volume":"85","author":"Mullin","year":"2004","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib46","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1073\/pnas.1119817109","article-title":"Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase","volume":"109","author":"Muratore","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.03.003_bib47","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1128\/AAC.01219-12","article-title":"Human cytomegalovirus inhibitor AL18 also possesses activity against influenza A and B viruses","volume":"56","author":"Muratore","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.03.003_bib48","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ofid\/ofw172.508","article-title":"S-033447\/S-033188, a novel small molecule inhibitor of cap-dependent endonuclease of influenza A and B virus: in vitro antiviral activity against clinical strains","volume":"3","author":"Noshi","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.003_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.003_bib50","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/nature07225","article-title":"The structural basis for an essential subunit interaction in influenza virus RNA polymerase","volume":"454","author":"Obayashi","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.03.003_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/cmdc.201300378","article-title":"The fight against the influenza A virus H1N1: synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors","volume":"9","author":"Pagano","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.antiviral.2019.03.003_bib52","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.antiviral.2013.05.014","article-title":"Inhibition of herpesvirus and influenza virus replication by blocking polymerase subunit interactions","volume":"99","author":"Pal\u00f9","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.003_bib53","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1128\/JVI.69.11.6932-6939.1995","article-title":"A 48-amino-acid region of influenza A virus PB1 protein is sufficient for complex formation with PA","volume":"69","author":"P\u00e9rez","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib54","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1128\/JVI.75.17.8127-8136.2001","article-title":"Functional analysis of PA binding by influenza a virus PB1: effects on polymerase activity and viral infectivity","volume":"75","author":"Perez","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature14008","article-title":"Structure of influenza A polymerase bound to the viral RNA promoter","volume":"516","author":"Pflug","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.03.003_bib56","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/454160a","article-title":"The contents of the syringe","volume":"454","author":"Salzberg","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.03.003_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jac\/dkp393","article-title":"BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses","volume":"65","author":"Shih","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2019.03.003_bib58","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/med.21401","article-title":"The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design","volume":"36","author":"Stevaert","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.antiviral.2019.03.003_bib59","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/emboj.2009.138","article-title":"Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase","volume":"28","author":"Sugiyama","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2019.03.003_bib60","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.chom.2010.05.009","article-title":"Influenza virus evolution, host adaptation, and pandemic formation","volume":"7","author":"Taubenberger","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.03.003_bib61","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bmcl.2013.11.019","article-title":"High-throughput docking for the identification of new influenza A virus polymerase inhibitors targeting the PA-PB1 protein-protein interaction","volume":"24","author":"Tintori","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2019.03.003_bib62","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1099\/0022-1317-77-9-2149","article-title":"Molecular assembly of the influenza virus RNA polymerase: determination of the subunit-subunit contact sites","volume":"77","author":"Toyoda","year":"1996","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.03.003_bib63","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1021\/acs.jmedchem.5b01935","article-title":"4,6- Diphenylpyridines as promising novel anti-influenza agents targeting the PA-PB1 protein-protein interaction: structure-activity relationships exploration with the aid of molecular modeling","volume":"59","author":"Trist","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.003_bib64","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1038\/s41598-017-10021-w","article-title":"Structure-based drug discovery for combating influenza virus by targeting the PA-PB1 interaction","volume":"7","author":"Watanabe","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.03.003_bib65","author":"WHO"},{"key":"10.1016\/j.antiviral.2019.03.003_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007517","article-title":"Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication","volume":"4","author":"Wunderlich","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.003_bib67","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/AAC.01419-10","article-title":"Identification of high-affinity PB1-derived peptides with enhanced affinity to the PA protein of influenza A virus polymerase","volume":"55","author":"Wunderlich","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.03.003_bib68","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2015.11.005","article-title":"Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase","volume":"125","author":"Yuan","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.003_bib69","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1038\/s41598-018-22875-9","article-title":"Exploring ugi-azide four-component reaction products for broad-spectrum influenza antivirals with a high genetic barrier to drug resistance","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T21:47:10Z","timestamp":1663105630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218306594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":69,"alternative-id":["S0166354218306594"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.03.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA-PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}